# Lineage Cell Therapeutics, Inc. (LCTX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Lineage Cell Therapeutics, Inc. (LCTX) is 4/100, ranked against 24,000+ stocks in 35 markets (Quality 27, Value 25, Momentum 19, each scored against its sector).

- StockRank: 4/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 27, Value 25, Momentum 19: each a 0-100 percentile within Healthcare.
- Position: #25,306 overall, #2,507 in Healthcare.
- Listing: United States, ASE; Healthcare / Biotechnology.
- Last close: 0.997 USD on 26 Oct 2026.
- Insider filings, last 180 days: no director or 5%+ holder trades with a stated value.

Source: https://moatmap.ai/stock/LCTX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker